1. Home
  2. DBD vs IDYA Comparison

DBD vs IDYA Comparison

Compare DBD & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Diebold Nixdorf Incorporated

DBD

Diebold Nixdorf Incorporated

N/A

Current Price

$52.02

Market Cap

2.3B

Sector

Technology

ML Signal

N/A

Logo IDEAYA Biosciences Inc.

IDYA

IDEAYA Biosciences Inc.

N/A

Current Price

$25.63

Market Cap

2.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DBD
IDYA
Founded
1859
2015
Country
United States
United States
Employees
N/A
145
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.5B
IPO Year
2023
2019

Fundamental Metrics

Financial Performance
Metric
DBD
IDYA
Price
$52.02
$25.63
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
15
Target Price
★ $85.00
$50.15
AVG Volume (30 Days)
343.9K
★ 1.1M
Earning Date
10-28-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 677.27
61.90
EPS
★ 0.77
N/A
Revenue
★ $3,805,700,000.00
$218,710,000.00
Revenue This Year
$1.93
N/A
Revenue Next Year
$2.54
$186.04
P/E Ratio
$65.29
★ N/A
Revenue Growth
1.46
★ 3024.43
52 Week Low
$49.77
$25.75
52 Week High
$92.09
$42.68

Technical Indicators

Market Signals
Indicator
DBD
IDYA
Relative Strength Index (RSI) 32.61 24.75
Support Level N/A N/A
Resistance Level $85.54 $29.74
Average True Range (ATR) 2.43 1.73
MACD -0.50 -0.54
Stochastic Oscillator 18.84 0.47

Price Performance

Historical Comparison
DBD
IDYA

About DBD Diebold Nixdorf Incorporated

Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries. The customer segments of the company are Banking, which offers integrated solutions for financial institutions, and Retail, which offers solutions, software, and services that improve the checkout process for retailers. A majority of its revenue is generated from the Banking segment.

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

Share on Social Networks: